Metabolic & Weight ManagementIn StockMetabolic & Weight Management
Tesofensine
Also known as: NS2330
Investigational triple monoamine reuptake inhibitor (not a peptide) studied in obesity and neurochemistry research.
Tesofensine (NS2330) is a small-molecule triple monoamine reuptake inhibitor — affecting serotonin, noradrenaline, and dopamine transporters — originally developed as a candidate for neurodegenerative conditions before being investigated in obesity-research contexts.Though not structurally a peptide, Tesofensine is commonly cataloged alongside research peptides because its research-use positioning and customer base overlap significantly.
Published studies include Phase 2 clinical trials in obesity research and preclinical neurochemistry studies on monoamine pathway pharmacology.Tesofensine is typically supplied in oral tablet form rather than as a lyophilized peptide for reconstitution.
Research applications
- Monoamine transporter pharmacology (SERT, NET, DAT)
- Obesity and appetite-regulation neurochemistry
- Neurodegenerative-disease research
- Comparative weight-management compound research
- Monoamine-based CNS pharmacology
Technical profile
- Net content
- 500 mcg (30 capsules)
- Molecular formula
- C17H23Cl2NO
- Molecular weight
- 327.27 g/mol
- CAS
- 195875-84-4
- Sequence
- Small molecule (not applicable)
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
Tesofensine is a serotonin-noradrenaline-dopamine reuptake inhibitor originally developed for neurodegenerative disorders. Research has revealed significant weight loss effects through appetite suppression and increased resting energy expenditure.
